Husam A. Alqaisi

Husam A. Alqaisi

Auto-generated profile, based on publicly available information

Husam A. Alqaisi

Division of Hematology and Medical Oncology, Department of Medicine, School of Medicine, University of Jordan, Amman, Jordan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
HAHusam A. Alqaisi
Husam A. Alqaisi
DCDavid E. Cohn
David E. Cohn
JCJing-Yi Chern
Jing-Yi Chern
LDLinda R. Duska
Linda R. Duska
AJAndrea Jewell
Andrea Jewell
SLStephanie Lheureux
Stephanie Lheureux
Purpose: Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody–drug conjugate directed at the MSLN antigen with a tubulin polymerization inhibitor. We assessed the safety, activity, and pharmacokinetics of the combination AR/bevacizumab (Bev; ARB) versus weekly paclitaxel/Bev (PB) in patients with platinum-resistant/refractory HGOC (prrHGOC). Patients and Methods: Following a run-in phase I study to assess ARB safety, patients with prrHGOC with centrally confirmed MSLN-positive expression were randomized to ARB or PB (weekly paclitaxel 80 mg/m2 with Bev 10 mg/kg biweekly). Patients were stratified by platinum resistance/refractory and prior Bev. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall response rate, safety, and blood-based angiome biomarker assessment. A futility analysis was planned after 35 PFS events. Results: The combination of Bev (10 mg/kg) biweekly with AR (2.2 mg/kg) weekly was well tolerated. About phase II results, MSLN positivity was 88%, and 57 patients were randomized (28 ARB and 29 PB). Forty-two percentage of patients received prior Bev, and 23% were platinum-refractory. At futility analysis, the median PFS was 5.3 and 12.7 months for ARB and PB, respectively [P = 0.03; HR = 2.02 (1.06–3.86)]. The overall response rate was 21% with ARB and 65% with PB. The most common treatment-related grade ≥3 adverse events were anemia (18%) with ARB and neutropenia (24%) with PB. Higher baseline levels of circulating IL6 were associated with worse PFS, and its levels decreased with PB treatment. Conclusions: Our study stopped at interim analysis highlighting the benefit of PB in prrHGOC as the standard of care.


17 March 2025
Verified
Other
Open access
PDF file
HAHusam A. Alqaisi
Husam A. Alqaisi
DCDavid E. Cohn
David E. Cohn
JCJing-Yi Chern
Jing-Yi Chern
LDLinda R. Duska
Linda R. Duska
AJAndrea Jewell
Andrea Jewell
SLStephanie Lheureux
Stephanie Lheureux
Figure S2: Figure 7: Mean ± SD concentration versus time profiles of AR (ADC), total antibody, DM4, and DM4-Me after administration of AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.

17 March 2025
Verified
Other
Open access
HAHusam A. Alqaisi
Husam A. Alqaisi
DCDavid E. Cohn
David E. Cohn
JCJing-Yi Chern
Jing-Yi Chern
LDLinda R. Duska
Linda R. Duska
AJAndrea Jewell
Andrea Jewell
SLStephanie Lheureux
Stephanie Lheureux
: Pharmacokinetic parameters of AR after administration of 2.2 mg/kg AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.

17 March 2025
Verified
Other
Open access
PDF file
HAHusam A. Alqaisi
Husam A. Alqaisi
DCDavid E. Cohn
David E. Cohn
JCJing-Yi Chern
Jing-Yi Chern
LDLinda R. Duska
Linda R. Duska
AJAndrea Jewell
Andrea Jewell
SLStephanie Lheureux
Stephanie Lheureux
Figure S3. Relationship between anetumab ravtansine AUC0-inf (A) and DM4 AUC0-168h (B) and best antitumor response.

17 March 2025
Verified
Other
Open access
PDF file
HAHusam A. Alqaisi
Husam A. Alqaisi
DCDavid E. Cohn
David E. Cohn
JCJing-Yi Chern
Jing-Yi Chern
LDLinda R. Duska
Linda R. Duska
AJAndrea Jewell
Andrea Jewell
SLStephanie Lheureux
Stephanie Lheureux
A randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory high grade ovarian cancer NCI trial#10150.